18f-fdg pet/ct in therapy response assessment: oligometastatic colorectal cancer

HIGHLIGHTS

  • who: Ibrahim Mansour Nasr from the of Medicine, Zagazig, Zagazeg have published the Article: 18F-FDG PET/CT in therapy response assessment: oligometastatic colorectal cancer, in the Journal: (JOURNAL)
  • what: Except for prescriptions containing metformin, which should be discontinued 48 h before the study, oral diabetic medications were used as recommended. The authors assessed 18F-FDG PET/CT for the evaluation of CRC therapy.
  • future: This study did not include patients who did PET/CT in the first day post treatment so to confirm its value in the prediction of success of ablation . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?